Cardiac Ablation Market Size, Share, Competitive Landscape and Trend Analysis Report, by Product, by Approach, by Application, by End Use : Global Opportunity Analysis and Industry Forecast, 2024-2033

Key Market Dynamics

Several people worldwide are diagnosed with cardiac arrhythmias, such as atrial fibrillation, ventricular tachycardia, and others. This increase has led to a greater demand for cardiac ablation procedures as a treatment option. Innovation in ablation technologies, such as radiofrequency, cryoablation, laser, and microwave, has improved the effectiveness, safety, and precision of ablation procedures. These advancements make ablation a more attractive option for both patients and healthcare providers. Cardiac ablation is generally less invasive compared to traditional surgical approaches. The reduced recovery time, lower risk of complications, and improved patient outcomes contribute to its growing popularity. All these factors are anticipated to drive the cardiac ablation market growth.

The high cost of cardiac ablation procedures and the equipment required for these procedures is a significant factor projected to hinder the growth of the cardiac ablation market size. Cardiac ablation involves specialized equipment like catheters, mapping systems, energy generators, and imaging technology. Advanced technologies like cryoablation or laser ablation are costly, requiring substantial capital investment by healthcare institutions. This high initial cost can deter smaller hospitals or clinics from offering ablation procedures, limiting market expansion.

The development of smaller, more efficient ablation catheters and mapping systems presents an opportunity for healthcare providers to offer more precise and effective treatments. Innovations in energy sources, like cryoablation and laser ablation, allow for more diverse treatment options and can lead to reduced complications. Cardiac ablation has traditionally been used to treat atrial fibrillation and other arrhythmias. However, there is growing interest in exploring ablation for other cardiac conditions, such as ventricular tachycardia and heart failure-related arrhythmias. All these factors are anticipated to drive the cardiac ablation market share.

Public Policies of Global Cardiac Ablation Market

Public Health Implications: Given the rising prevalence of AFib and its impact on health, public policy plays a crucial role in ensuring access to effective treatments like cardiac ablation. Here are some considerations:

Guidelines and Standards: International experts recently published a consensus statement on treating AFib with catheter or surgical ablation. This document provides best practice standards and practical advice for patient selection, procedural performance, and post-procedure management.

Patient Selection: Public policy should promote equitable access to cardiac ablation for eligible patients. Guidelines recommend ablation as a first-line treatment for symptomatic patients with recurrent AFib. Additionally, patients with heart failure may benefit from ablation to alleviate symptoms and improve prognosis.

Healthcare Infrastructure: Policymakers need to ensure that healthcare systems have the necessary infrastructure, skilled personnel, and resources to perform cardiac ablation procedures effectively. This includes training healthcare professionals and maintaining high-quality facilities.

Research and Innovation: Public funding and support for research are essential to advance ablation techniques and improve outcomes. Policymakers should encourage collaboration between researchers, clinicians, and industry to enhance treatment options.

Patient Education: Public health campaigns can raise awareness about AFib, its symptoms, and available treatments. Educating patients about the benefits and risks of cardiac ablation empowers them to make informed decisions.

Market Segmentation

The cardiac ablation market is segmented into product, approach, application, end use, and region. On the basis of product, the market is divided into radiofrequency (RF) , ablators, electrical ablators, cryoablation devices, ultrasound ablators, and others. On the basis of approach, the market is classified into catheter-based and open/surgical. On the basis of application, the market is divided into atrial fibrillation & flutter, tachycardia, and others. As per end use, the market is classified into hospitals, ambulatory surgical centers, cardiac centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Regional Market Outlook

North America has a high prevalence of cardiac arrhythmias, including atrial fibrillation, ventricular tachycardia, and supraventricular tachycardia. The increasing diagnosis rates and awareness about arrhythmias contribute to the demand for cardiac ablation procedures as a treatment option. North America is a leader in medical technology innovation, with many companies based in the U.S. and Canada focusing on developing advanced ablation devices and techniques. Innovations like cryoablation, laser ablation, and more precise mapping technologies have improved the safety and efficacy of ablation procedures, making them more attractive to healthcare providers. All these factors are anticipated to drive the cardiac ablation market share in North America.

In the U.S., NYU Langone’s Heart Rhythm Center tested a new ablation device called the Qdot Micro. This device generates approximately three times the heating power of conventional ablation devices. Dr. Larry A. Chinitz, the director of NYU Langone’s Heart Rhythm Center, led the trial, making NYU Langone the first institution in the U.S. to evaluate this innovative technology.

• In April, 2022, the University of Ottawa Heart Institute (UOHI) performed the first patient procedures in North America using a new technology that is expected to reduce wait times for ablations while making these procedures quicker and safer.
• The QDOT MICRO technology – developed by Biosense Webster Inc. – has been proven to reduce total procedure times without compromising clinical outcomes. A feature of this technology is a temperature-controlled ablation mode that allows 90 watts of radiofrequency power for up to four seconds. Current practice with irrigated catheters involves the delivery of only moderate power (20 to 40 watts) for as long as 40 seconds.

Competitive Landscape

The major players operating in the cardiac ablation market include Abbott Laboratories, Medtronic, Biosense Webster (Johnson & Johnson) , Angiodynamics, Boston Scientific Corporation, Atricure, and Japan Lifeline.

Other players in cardiac ablation market include Teleflex Incorporated, St. Jude Medical Inc, Lepu Medical Technology (Beijing) Co., Ltd, and MicroPort Scientific Corporation.

Recent Key Strategies and Developments

• On September 06, 2022, Johnson & Johnson MedTech, through its subsidiary Biosense Webster, Inc., announced the launch of the OCTARAY Mapping Catheter with TRUEref Technology. This catheter is part of the CARTO 3 Version 7 System, designed for mapping cardiac arrhythmias, including atrial fibrillation (AFib) .
• On August 23, 2022, Medtronic, a prominent global healthcare technology company, acquired Affera, Inc. This acquisition aims to broaden Medtronic's cardiac ablation portfolio by adding its first cardiac mapping and navigation platform, which integrates diagnostic capabilities, focused pulsed field ablation, and radiofrequency ablation solutions.

Industry Trends

• As of May 2024, catheter ablation remains a leading rhythm-control method for atrial fibrillation (AF) . Traditional ablation techniques, using radiofrequency or cryoablation, pose risks like hemidiaphragmatic paralysis and atrioesophageal fistula. Pulsed field ablation (PFA) emerges as a groundbreaking alternative, offering selective tissue targeting and reduced ablation times, minimizing collateral damage.
• In May 2023, according to a study being presented at the American College of Cardiology's Annual Scientific Session Together With the World Congress of Cardiology, a new ablation technology known as pulsed-field ablation was successful at eliminating episodes of abnormal heart rhythms for 12 months in up to two-thirds of patients.

Key Sources Referred

1. Annual Reports
2. Investor Presentations
3. Press Release
4. Research Paper
5. D&B Hoovers
6. ZoomInfo Technologies LLC
7. National Library of Medicine
8. The American Society of Microbiology
9. Science Direct Journal
10. American Heart Association

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cardiac ablation market analysis from 2023 to 2033 to identify the prevailing cardiac ablation market opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the cardiac ablation market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Cardiac ablation industry player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

Apart from the points mentioned above, the report includes the analysis of the regional as well as global cardiac ablation market trends, key players, market segments, application areas, and market growth strategies.